Axsome Therapeutics (AXSM) Capital Leases (2024 - 2026)

Axsome Therapeutics (AXSM) has 3 years of Capital Leases data on file, last reported at $5.8 million in Q1 2026.

• For the quarter ending Q1 2026, Capital Leases rose 58.8% year-over-year to $5.8 million; the trailing twelve-month figure through Mar 2026 stood at $5.8 million (up 58.8% YoY), and the FY2025 full-year result was $4.2 million, up 42.92% from the prior year.
• Capital Leases climbed to $5.8 million in Q1 2026, from $4.2 million in the prior quarter.
• In the past five years, Capital Leases ranged from a high of $5.8 million in Q1 2026 to a low of $1.7 million in Q1 2024.
• A 3-year average of $3.6 million and a median of $3.7 million in 2025 frame the typical range for Capital Leases.
• Peak annual rise in Capital Leases reached 116.85% in 2025, while the deepest fall reached 25.36% in 2025.
• Tracing AXSM's Capital Leases over 3 years: stood at $2.9 million in 2024, then soared by 42.92% to $4.2 million in 2025, then soared by 38.94% to $5.8 million in 2026.
• Business Quant data shows AXSM's Capital Leases at $5.8 million in Q1 2026, $4.2 million in Q4 2025, and $4.7 million in Q3 2025.